New diabetes pill rybelsus under Real-World safety check in korea

NCT ID NCT05714683

First seen Jan 08, 2026 · Last updated May 15, 2026 · Updated 17 times

Summary

This study will monitor about 600 adults with type 2 diabetes who are starting Rybelsus as part of their normal care. The goal is to track any side effects and how well the medicine controls blood sugar over 26 weeks. Participants take the pill as prescribed by their doctor, with no extra tests or treatments beyond routine practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.